

Innovation all for the patients



Roche A member of the Roche group

Verastem Oncology's Announcement Regarding Avutometinib  
(Completion of Rolling NDA Submission to the FDA for Avutometinib plus Defactinib  
as a Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer)

TOKYO, November 1, 2024 -- [Chugai Pharmaceutical Co., Ltd.](#) (TOKYO: 4519) announced that [Verastem Oncology](#) issued a press release on October 31 about completion of rolling New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for avutometinib plus defactinib as a treatment for recurrent KRAS mutant low-grade serous ovarian cancer. Avutometinib, a RAF/MEK clamp, was created by Chugai, and its clinical development is being conducted by Verastem Oncology.

Please refer to the link below for details of the Verastem Oncology's press release:

Verastem Oncology Completes Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as a Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer

<https://investor.verastem.com/news-releases/news-release-details/verastem-oncology-completes-rolling-nda-submission-fda>

###